ORIGINAL RESEARCH original O OR ORI ORIG BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Clinical Efficacy clinical C Cl Cli Clin BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 - 1 9 0 0 0 0 1
Infections in infections I In Inf Infe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Yuanbing Wu yuanbing Y Yu Yua Yuan BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 .... 4 10 0 0 0 0 1
Qian Li qian Q Qi Qia Qian BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ..... 5 10 0 0 0 0 1
Xiaohui Hu xiaohui X Xi Xia Xiao BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
Received: October received: R Re Rec Rece BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :,/:,/:, 8 10 0 0 0 0 1
Ó The ó Ó Ó Ó Ó BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 1 () 2 2 0 0 0 0 1
ABSTRACT ABSTRACT abstract A AB ABS ABST BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
Introduction: Carbapenem-resistant introduction: I In Int Intr BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :- 2 9 0 0 0 0 1
(CRO) have (cro) ( (C (CR (CRO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 () 2 9 0 0 0 0 1
issue. However, issue. i is iss issu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 ., 2 9 0 0 0 0 1
antibiotics for antibiotics a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
limited. Polymyxins, limited. l li lim limi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 .,, 3 10 0 0 0 0 1
represent the represent r re rep repr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
against CRO against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 .- 2 9 0 0 0 0 1
rospectively evaluate rospectively r ro ros rosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
infections among infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
diseases. diseases. diseases. d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 2 0 0 0 0 1
Methods: Between methods: M Me Met Meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 : 1 8 0 0 0 0 1
2023, a 2023, 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 1 , 1 8 0 0 0 0 1
diagnosed with diagnosed d di dia diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
Hematology. The hematology. H He Hem Hema BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 . 1 8 0 0 0 0 1
clinical efficacy, clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ,, 2 10 0 0 0 0 1
reactions, and reactions, r re rea reac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ,--. 4 8 0 0 0 0 1
Results: The results: R Re Res Resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 :- 2 8 0 0 0 0 1
tive rate tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 no 0 9 0 0 0 0 1
CRO infection cro C CR CRO CRO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 ., 2 7 0 0 0 0 1
clearance rate clearance c cl cle clea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ..- 3 8 0 0 0 0 1
ment, nephrotoxicity ment, m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 ,., 3 9 0 0 0 0 1
neurotoxicity in neurotoxicity n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 .,- 3 8 0 0 0 0 1
all-cause mortality all-cause a al all all- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 -.. 3 9 0 0 0 0 1
logistic analysis logistic l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
course and course c co cou cour BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
antimicrobials were antimicrobials a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 4 - 1 8 0 0 0 0 1
ing the ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 4 . 1 8 0 0 0 0 1
Conclusion: Our conclusion: C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 : 1 8 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
clinical efficacy clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 , 1 9 0 0 0 0 1
low risk low l lo low low BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 4 . 1 9 0 0 0 0 1
evidence of evidence e ev evi evid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
safety of safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
patients. High-quality patients. p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 .- 2 8 0 0 0 0 1
trials are trials t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
beneficial role beneficial b be ben bene BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 . 1 6 0 0 0 0 1
Keywords: Polymyxins; keywords: K Ke Key Keyw BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 8 :; 2 4 0 0 0 0 1
Colistin; Colistin; colistin; C Co Col Coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ; 1 2 0 0 0 0 1
Hematological diseases; hematological H He Hem Hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ;- 2 10 0 0 0 0 1
organisms; Infections organisms; o or org orga BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 8 ; 1 4 0 0 0 0 1
Yuanbing Wu, yuanbing Y Yu Yua Yuan BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 , 1 10 0 0 0 0 1
contributed equally contributed c co con cont BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 8 . 1 7 0 0 0 0 1
Y. Wu y. Y Y. Y. Y. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ...... 6 10 0 0 0 0 1
B. Liu b. B B. B. B. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 1 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 , 1 9 0 0 0 0 1
Hongci Hematology, hongci H Ho Hon Hong BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ,,, 3 8 0 0 0 0 1
China China china C Ch Chi Chin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 9 no 0 1 0 0 0 0 1
H. Bao h. H H. H. H. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 ..().() 7 5 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 8 0 0 0 0 1
Research Center research R Re Res Rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 10 , 1 10 0 0 0 0 1
Affiliated Hospital affiliated A Af Aff Affi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 9 0 0 0 0 1
215000, Jiangsu, 215000, 2 21 215 2150 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 10 ,, 2 4 0 0 0 0 1
e-mail: wudepei@suda.edu.cn e-mail: e e- e-m e-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 10 -:@.. 5 5 0 0 0 0 1
X. Hu x. X X. X. X. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 . 1 2 0 1 0 0 1
e-mail: huxiaohui@suda.edu.cn e-mail: e e- e-m e-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 11 -:@.. 5 10 0 1 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 ():- 4 7 0 1 1 1 0
https://doi.org/10.1007/s40121-023-00909-8 https://doi.org/10.1007/s40121-023-00909-8 https://doi.org/10.1007/s40121-023-00909-8 h ht htt http BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 0 11 ://././--- 10 10 0 1 0 0 0
Key Summary key K Ke Key Key BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Why carry why W Wh Why Why BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 ? 1 10 0 1 0 0 1
Colistin sulfate colistin C Co Col Coli BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
available in available a av ava avai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
need to need n ne nee need BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
with carbapenem-resistant with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
(CRO) infections. (cro) ( (C (CR (CRO BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 (). 3 4 0 0 0 0 1
We retrospectively we W We We We BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 10 0 0 0 0 1
microbial response, microbial m mi mic micr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,-- 3 8 0 0 0 0 1
mortality, and mortality, m mo mor mort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 10 0 0 0 0 1
at discontinuation. at a at at at BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 4 0 0 0 0 1
What was what W Wh Wha What BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
Colistin sulfate colistin C Co Col Coli BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
efficacy and efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 , 1 9 0 0 0 0 1
low risk low l lo low low BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 1 no 0 7 0 0 0 0 1
infections. The infections. i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 8 0 0 0 0 1
combination medication combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 7 0 0 0 0 1
antimicrobials were antimicrobials a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
affecting the affecting a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
sulfate. sulfate. sulfate. s su sul sulf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 . 1 2 0 0 0 0 1
Prospective, multicenter, prospective, P Pr Pro Pros BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 ,, 2 8 0 0 0 0 1
controlled, and controlled, c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,- 2 9 0 0 0 0 1
needed to needed n ne nee need BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
safety of safety s sa saf safe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 9 0 0 0 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
In recent in I In In In BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 2 , 1 10 0 0 0 0 1
of broad-spectrum of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -,- 3 9 0 0 0 0 1
bacteria have bacteria b ba bac bact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 9 0 0 0 0 1
delay targeted delay d de del dela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
health. Among health. h he hea heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 .,- 3 8 0 0 0 0 1
organisms (CRO), organisms o or org orga BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 (),-- 5 9 0 0 0 0 1
tant Enterobacteriaceae tant t ta tan tant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 (),-- 5 9 0 0 0 0 1
tant Acinetobacter tant t ta tan tant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 (), 3 8 0 0 0 0 1
carbapenem-resistant Pseudomonas carbapenem-resistant c ca car carb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 - 1 8 0 0 0 0 1
(CRPA), are (crpa), ( (C (CR (CRP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 (),- 4 9 0 0 0 0 1
infection-associated morbidity infection-associated i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
worldwide and worldwide w wo wor worl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
World Health world W Wo Wor Worl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 () 2 7 0 0 0 0 1
priority pathogens priority p pr pri prio BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 9 0 0 0 0 1
lic health lic l li lic lic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 [,]. 4 3 0 0 0 0 1
Patients with patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 7 0 0 0 0 1
are at are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [,]. 4 9 0 0 0 0 1
patients have patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
tions and tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
clinical departments clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
odeficiencies and odeficiencies o od ode odef BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,, 2 7 0 0 0 0 1
hematopoietic stem hematopoietic h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 () 2 9 0 0 0 0 1
resulting in resulting r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [,,]. 5 8 0 0 0 0 1
revealed that revealed r re rev reve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
infections in infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
malignancies ranges malignancies m ma mal mali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 .[-]. 5 8 0 0 0 0 1
Unfortunately, the unfortunately, U Un Unf Unfo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 8 0 0 0 0 1
antimicrobials for antimicrobials a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
ited. Polymyxins, ited. i it ite ited BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 .,'''' 6 9 0 0 0 0 1
effective against effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
returned to returned r re ret retu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
defense [10, defense d de def defe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [,]. 4 3 0 0 0 0 1
Currently, only currently, C Cu Cur Curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 8 0 0 0 0 1
are available are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,.., 4 10 0 0 0 0 1
(PMB), colistin (pmb), ( (P (PM (PMB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 (),, 4 8 0 0 0 0 1
sodium (CMS) sodium s so sod sodi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ()[].- 6 8 0 0 0 0 1
ies have ies i ie ies ies BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
and PMB and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
[13-17]. However, [13-17]. [ [1 [13 [13- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 [-]., 5 7 0 0 0 0 1
effects of effects e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,- 2 8 0 0 0 0 1
ity, must ity, i it ity ity, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
[18]. Nephrotoxicity [18]. [ [1 [18 [18] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 4 []. 3 9 0 0 0 0 1
in up in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
CMS or cms C CM CMS CMS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 [].,- 5 8 0 0 0 0 1
hyperpigmentation remains hyperpigmentation h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 -- 2 8 0 0 0 0 1
life concern life l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 []. 3 8 0 0 0 0 1
events have events e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
of PMB of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 3 0 0 0 0 1
As one as A As As As BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
been shown been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
clinical and clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
nephrotoxicity incidence nephrotoxicity n ne nep neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
of CRO of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [-]., 5 8 0 0 0 0 1
studies have studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
safety in safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
logical diseases. logical l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ., 2 9 0 0 0 0 1
real-world retrospective real-world r re rea real BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 9 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
with the with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
clinical use clinical c cl cli clin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 5 0 0 0 0 1
142 142 142 1 14 142 142 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 1 11 no 0 1 0 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 ():- 4 10 0 1 1 0 0
METHODS METHODS methods M ME MET METH BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 10 0 1 0 0 1
Study Design study S St Stu Stud BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 10 0 1 0 0 1
This observational, this T Th Thi This BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,,- 3 9 0 0 0 0 1
clinical study clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
Suzhou Hongci suzhou S Su Suz Suzh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ,, 2 8 0 0 0 0 1
Province, China. province, P Pr Pro Prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,. 2 8 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
between April between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
reviewed. This reviewed. r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
Committee of committee C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
Hematology and hematology H He Hem Hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
consent because consent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
Furthermore, the furthermore, F Fu Fur Furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
accordance with accordance a ac acc acco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ( 1 9 0 0 0 0 1
revised in revised r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ). 2 3 0 0 0 0 1
The primary the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 7 0 0 0 0 1
clinical efficacy, clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,,-- 4 10 0 0 0 0 1
cause mortality, cause c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
events at events e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
were factors were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 6 0 0 0 0 1
Patients Patients patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
Adult patients adult A Ad Adu Adul BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 : 1 9 0 0 0 0 1
(1) were (1) ( (1 (1) (1) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 2 () 2 9 0 0 0 0 1
(including malignant (including ( (i (in (inc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ( 1 8 0 0 0 0 1
anemia); (2) anemia); a an ane anem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 );() 4 8 0 0 0 0 1
high suspicion high h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 2 . 1 8 0 0 0 0 1
of CRO of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 8 0 0 0 0 1
based on based b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
specimens and specimens s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 8 0 0 0 0 1
based on based b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ',, 3 9 0 0 0 0 1
and laboratory and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 , 1 8 0 0 0 0 1
and inflammatory and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 , 1 7 0 0 0 0 1
absence of absence a ab abs abse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
results; (3) results; r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ;();() 6 9 0 0 0 0 1
received colistin received r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 , 1 9 0 0 0 0 1
either alone either e ei eit eith BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 7 0 0 0 0 1
antimicrobials. Patients antimicrobials. a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 . 1 8 0 0 0 0 1
were: (1) were: w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 :();() 6 10 0 0 0 0 1
study drug; study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ;()--- 6 8 0 0 0 0 1
tive bacteria; tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ;()- 4 9 0 0 0 0 1
ment; (5) ment; m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ;();() 6 9 0 0 0 0 1
severe organ severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 (/ 2 7 0 0 0 0 1
dysfunction grade dysfunction d dy dys dysf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 [ 1 7 0 0 0 0 1
Common Terminology common C Co Com Comm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 10 0 1 0 0 1
Events [version events E Ev Eve Even BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 5 [.]). 5 5 0 1 0 0 1
Data Collection data D Da Dat Data BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 10 0 1 0 0 1
Patient data patient P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
tronic medical tronic t tr tro tron BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 . 1 8 0 0 0 0 1
mainly includes mainly m ma mai main BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
istics: age, istics: i is ist isti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 :,,- 4 8 0 0 0 0 1
ease, hematopoietic ease, e ea eas ease BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 , 1 8 0 0 0 0 1
status, site status, s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,,- 3 8 0 0 0 0 1
gens, infection gens, g ge gen gens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ,, 2 8 0 0 0 0 1
therapy, clinical therapy, t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,, 2 8 0 0 0 0 1
adverse reactions, adverse a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,,. 3 8 0 0 0 0 1
All patients all A Al All All BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
intravenous colistin intravenous i in int intr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ( 1 9 0 0 0 0 1
injection, Shanghai injection, i in inj inje BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,- 2 7 0 0 0 0 1
tical Co. tical t ti tic tica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ..,,) 5 8 0 0 0 0 1
dose of dose d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 .-., 4 8 0 0 0 0 1
2-3 intravenous 2-3 2 2- 2-3 2-3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 5 -. 2 8 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
package insert, package p pa pac pack BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 , 1 8 0 0 0 0 1
optimal clinical optimal o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
[24], as [24], [ [2 [24 [24] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 5 [], 3 8 0 0 0 0 1
context of context c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 '. 2 8 0 0 0 0 1
The clinical the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
treatment was treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
biological criteria biological b bi bio biol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
tinuation. Patients tinuation. t ti tin tinu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 . 1 8 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 , 1 9 0 0 0 0 1
course of course c co cou cour BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 .- 2 8 0 0 0 0 1
cacy was cacy c ca cac cacy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 - 1 7 0 0 0 0 1
toms and toms t to tom toms BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
treatment, while treatment, t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 , 1 8 0 0 0 0 1
the aggravation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
signs during signs s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 4 0 0 0 0 1
CRO strains cro C CR CRO CRO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 7 0 0 0 0 1
specimens of specimens s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,- 2 8 0 0 0 0 1
tum, alveolar tum, t tu tum tum, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ,,. 3 7 0 0 0 0 1
pathogenic bacteria pathogenic p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
fied through fied f fi fie fied BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 -/ 2 8 0 0 0 0 1
ionization time-of-flight ionization i io ion ioni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 --. 3 8 0 0 0 0 1
addition, when addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 , 1 8 0 0 0 0 1
infection in infection i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 , 1 10 0 0 0 0 1
when empirical when w wh whe when BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 - 1 8 0 0 0 0 1
tive for tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 ,- 2 7 0 0 0 0 1
generation sequencing generation g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 () 2 7 0 0 0 0 1
bacterial identification bacterial b ba bac bact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
resistance genes resistance r re res resi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 []. 3 8 0 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 ():- 4 10 0 1 1 0 0
143 143 143 1 14 143 143 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 11 no 0 1 0 1 0 0 0
antimicrobial susceptibility antimicrobial a an ant anti BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
formed according formed f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
tory Standards tory t to tor tory BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 0 () 2 8 0 0 0 0 1
(M100), using (m100), ( (M (M1 (M10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 (),- 4 7 0 0 0 0 1
method. The method. m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 .,- 3 8 0 0 0 0 1
glycosides, quinolones, glycosides, g gl gly glyc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,,,, 4 9 0 0 0 0 1
and aztreonam and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
CLSI breakpoints. clsi C CL CLS CLSI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 . 1 9 0 0 0 0 1
for colistin for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
bial Susceptibility bial b bi bia bial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ()(/ 4 9 0 0 0 0 1
l, R l, l l, l, l, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,/)[,]. 7 9 0 0 0 0 1
considered a considered c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 8 0 0 0 0 1
However, the however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 ,- 2 8 0 0 0 0 1
logical responses logical l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
same causative same s sa sam same BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
invalid. invalid. invalid. i in inv inva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 1 0 0 0 0 1
Adverse events adverse A Ad Adv Adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 8 0 0 0 0 1
fate were fate f fa fat fate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,- 2 9 0 0 0 0 1
toxicity, hepatotoxicity, toxicity, t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,,. 3 9 0 0 0 0 1
renal and renal r re ren rena BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
day before day d da day day BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
sulfate. Increased sulfate. s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 .() 3 10 0 0 0 0 1
by subtracting by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
commencement of commencement c co com comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 9 0 0 0 0 1
impairment was impairment i im imp impa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
ney Disease: ney n ne ney ney BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 : 1 7 0 0 0 0 1
(KDIGO) criteria (kdigo) ( (K (KD (KDI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ()[].- 6 9 0 0 0 0 1
ated according ated a at ate ated BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 (.). 4 7 0 0 0 0 1
Statistical Analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 10 0 0 0 0 1
SPSS22.0 software spss22.0 S SP SPS SPSS BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 3 .- 2 9 0 0 0 0 1
yses (IBM yses y ys yse yses BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 (.,,). 6 9 0 0 0 0 1
presented as presented p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 (),, 4 8 0 0 0 0 1
(range). Student's (range). ( (r (ra (ran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 ().'- 5 9 0 0 0 0 1
continuous variables continuous c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 . 1 9 0 0 0 0 1
Fisher's exact fisher's F Fi Fis Fish BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 3 '- 2 9 0 0 0 0 1
ical variables. ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 .-. 3 10 0 0 0 0 1
the univariate the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 8 0 0 0 0 1
multivariate logistic multivariate m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 - 1 9 0 0 0 0 1
ther analysis. ther t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 3 .- 2 9 0 0 0 0 1
to demonstrate to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 .- 2 9 0 0 0 0 1
tailed p-value tailed t ta tai tail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 -. 2 9 0 0 0 0 1
difference. difference. difference. d di dif diff BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 . 1 2 0 0 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 3 5 no 0 10 0 1 0 0 1
Patient Demographic patient P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 10 0 1 0 0 1
Characteristics Characteristics characteristics C Ch Cha Char BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 4 0 1 0 0 1
Patients who patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
between April between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 7 0 0 0 0 1
enrolled. Of enrolled. e en enr enro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ., 2 10 0 0 0 0 1
118 were 118 1 11 118 118 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
the inclusion the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.). 4 9 0 0 0 0 1
summarized the summarized s su sum summ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 - 1 8 0 0 0 0 1
ical characteristics ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 - 1 9 0 0 0 0 1
ulation. The ulation. u ul ula ulat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 . 1 8 0 0 0 0 1
43.92 ± 43.92 4 43 43. 43.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 ..,(.) 6 8 0 0 0 0 1
females and females f fe fem fema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.).- 5 8 0 0 0 0 1
mon hematological mon m mo mon mon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
leukemia (49.2%), leukemia l le leu leuk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (.),- 5 7 0 0 0 0 1
phoblastic leukemia phoblastic p ph pho phob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (.), 4 8 0 0 0 0 1
syndrome (18.6%), syndrome s sy syn synd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.), 4 7 0 0 0 0 1
(10.2%). Among (10.2%). ( (1 (10 (10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 (.).,(.) 8 7 0 0 0 0 1
received allogeneic received r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
transplantation, and transplantation, t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ,(.) 4 7 0 0 0 0 1
chemotherapy. chemotherapy. chemotherapy. c ch che chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 . 1 2 0 0 0 0 1
All patients all A Al All All BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 7 0 0 0 0 1
infections, and infections, i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ,- 2 8 0 0 0 0 1
tion was tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (.),- 5 8 0 0 0 0 1
stream (39.8%) stream s st str stre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.)(.). 7 8 0 0 0 0 1
Among them, among A Am Amo Amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 , 1 8 0 0 0 0 1
seen in seen s se see seen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.).() 6 9 0 0 0 0 1
was the was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 7 0 0 0 0 1
sterile specimens, sterile s st ste ster BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ,(.) 4 8 0 0 0 0 1
and CRPA and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.)., 5 8 0 0 0 0 1
other CRE other o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 (.)- 4 8 0 0 0 0 1
obacter cloacae obacter o ob oba obac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 . 1 9 0 0 0 0 1
patients, 33.1% patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ,. 2 8 0 0 0 0 1
one CRO one o on one one BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 . 1 3 0 0 0 0 1
Colistin Sulfate colistin C Co Col Coli BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
Overall, 118 overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 , 1 10 0 0 0 0 1
doses of doses d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 .-./ 4 8 0 0 0 0 1
treatment duration treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ..(-- 5 8 0 0 0 0 1
30) days. 30) 3 30 30) 30) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 ). 2 8 0 0 0 0 1
17.58 ± 17.58 1 17 17. 17.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 ...(.) 6 8 0 0 0 0 1
patients were patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ..- 3 9 0 0 0 0 1
(17.8%) patients (17.8%) ( (1 (17 (17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 (.)- 4 9 0 0 0 0 1
ment for ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ,(.) 4 8 0 0 0 0 1
8-14 days, 8-14 8 8- 8-1 8-14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 -,(.)[. 7 9 0 0 0 0 1
144 144 144 1 14 144 144 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 11 no 0 1 0 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 ():- 4 10 0 1 1 0 0
nine (7.6%) nine n ni nin nine BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (.) 3 9 1 0 0 0 1
monotherapy. Forty monotherapy. m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 .(.) 4 9 1 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 8 1 0 0 0 1
antibacterial agent, antibacterial a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,(.), 5 10 1 0 0 0 1
and 14 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (.) 3 9 1 0 0 0 1
antibacterial agents. antibacterial a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 . 1 9 1 0 0 0 1
in combination in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 0 no 0 9 1 0 0 0 1
carbapenems, aminoglycosides, carbapenems, c ca car carb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,,, 3 8 1 0 0 0 1
fosfomycin, fosfomycin, fosfomycin, f fo fos fosf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 2 1 0 0 0 1
tigecycline, tigecycline, tigecycline, t ti tig tige BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 2 1 0 0 0 1
aztreonam, aztreonam, aztreonam, a az azt aztr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 2 1 0 0 0 1
etc. etc. etc. e et etc etc. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 . 1 1 1 0 0 0 1
(Table 1). (table ( (T (Ta (Tab BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 (). 3 2 1 0 0 0 1
Clinical and clinical C Cl Cli Clin BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 10 0 0 0 0 1
Based on based B Ba Bas Base BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 9 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 ,- 2 9 0 0 0 0 1
vant variables vant v va van vant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 no 0 9 0 0 0 0 1
effective and effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 . 1 8 0 0 0 0 1
demographic and demographic d de dem demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 8 0 0 0 0 1
clinical outcomes clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
sented below sented s se sen sent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 ., 2 8 0 0 0 0 1
response was response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 (.), 4 9 0 0 0 0 1
and 30 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 (.)- 4 9 0 0 0 0 1
ment failure. ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 .- 2 9 0 0 0 0 1
ences between ences e en enc ence BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 no 0 8 0 0 0 0 1
ineffective groups ineffective i in ine inef BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ([.), 5 10 0 0 0 0 1
weight, gender, weight, w we wei weig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 ,,, 3 8 0 0 0 0 1
hematopoietic stem hematopoietic h he hem hema BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 , 1 9 0 0 0 0 1
infection sites, infection i in inf infe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 ,. 2 9 1 0 0 0 1
ineffective group, ineffective i in ine inef BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 9 1 0 0 0 1
effective group effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
of treatment of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 (...;.) 7 9 1 0 0 0 1
received a received r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
sulfate (18.58 sulfate s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 (..... 6 9 1 0 0 0 1
IU, p iu, I IU IU, IU, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 ,.).. 5 8 1 0 0 0 1
IU/day was iu/day I IU IU/ IU/d BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 / 1 8 1 0 0 0 1
favorable efficacy favorable f fa fav favo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 8 1 0 0 0 1
IU/day (60.2% iu/day I IU IU/ IU/d BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 /(...,.). 9 9 1 0 0 0 1
to those to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 9 1 0 0 0 1
of [ of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 [ 1 9 1 0 0 0 1
rate (88.4% rate r ra rat rate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 (..., 5 4 1 0 0 0 1
= 0.002). = = = = = BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 4 .). 3 3 1 0 0 0 1
comparisons of comparisons c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 9 1 0 0 0 1
ment durations ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 - 1 8 1 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 -[ 2 7 1 0 0 0 1
advantageous in advantageous a ad adv adva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 9 1 0 0 0 1
ment duration ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 [(.).- 6 9 1 0 0 0 1
ever, there ever, e ev eve ever BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 8 1 0 0 0 1
efficacy between efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
8-14 days 8-14 8 8- 8-1 8-14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 -[(.). 6 8 1 0 0 0 1
with the with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 10 1 0 0 0 1
the clinically the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
with colistin with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
antibiotics had antibiotics a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
response rate response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 7 1 0 0 0 1
(p = (p ( (p (p (p BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 (.). 4 9 1 0 0 0 1
Fig. 1 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ..- 3 10 1 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ():- 4 10 1 1 1 0 0
145 145 145 1 14 145 145 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 11 no 0 1 1 1 0 0 0
Table 1 table T Ta Tab Tabl BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
Characteristics Characteristics characteristics C Ch Cha Char BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
Effective group effective E Ef Eff Effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 () 2 5 0 1 0 0 1
Ineffective group ineffective I In Ine Inef BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 () 2 5 0 1 0 0 1
Total Total total T To Tot Tota BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 6 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 () 2 10 0 1 0 0 1
t/v 2 t/v t t/ t/v t/v BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 / 1 10 0 1 0 0 1
value value value v va val valu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 1
p-value p-value p-value p p- p-v p-va BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 10 0 1 0 0 1
Age, years age, A Ag Age Age, BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 ,() 3 10 0 1 0 0 1
42.81 ± 42.81 4 42 42. 42.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 .. 2 6 0 1 0 0 1
47.20 ± 47.20 4 47 47. 47.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 .. 2 6 0 1 0 0 1
43.92 ± 43.92 4 43 43. 43.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 ... 3 8 0 1 0 0 1
0.190 0.190 0.190 0 0. 0.1 0.19 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 . 1 2 0 1 0 0 1
Weight, kg weight, W We Wei Weig BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 ,() 3 10 0 1 0 0 1
59.30 ± 59.30 5 59 59. 59.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 .. 2 6 0 1 0 0 1
54.78 ± 54.78 5 54 54. 54.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 .. 2 6 0 1 0 0 1
57.90 ± 57.90 5 57 57. 57.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 ... 3 8 0 1 0 0 1
0.151 0.151 0.151 0 0. 0.1 0.15 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 . 1 2 0 1 0 0 1
Gender, n gender, G Ge Gen Gend BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 2 ,() 3 10 0 0 0 0 1
Female Female female F Fe Fem Fema BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 2 no 0 6 0 0 0 0 1
35 (39.8%) 35 3 35 35 35 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
17 (56.7%) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
52 (44.1%) 52 5 52 52 52 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
2.59 2.59 2.59 2 2. 2.5 2.59 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 2 . 1 4 0 0 0 0 1
0.107 0.107 0.107 0 0. 0.1 0.10 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 2 . 1 5 0 0 0 0 1
Male Male male M Ma Mal Male BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 2 no 0 4 0 0 0 0 1
53 (60.2%) 53 5 53 53 53 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
13 (43.3%) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
66 (55.9%) 66 6 66 66 66 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 2 (.) 3 10 0 0 0 0 1
Type of type T Ty Typ Type BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 ,() 3 10 0 0 0 0 1
Acute myeloid acute A Ac Acu Acut BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 10 0 0 0 0 1
45 (51.1%) 45 4 45 45 45 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (.) 3 4 0 0 0 0 1
13 (43.3%) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (.) 3 4 0 0 0 0 1
58 (49.2%) 58 5 58 58 58 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (.) 3 4 0 0 0 0 1
2.95 2.95 2.95 2 2. 2.9 2.95 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 . 1 2 0 0 0 0 1
0.400 0.400 0.400 0 0. 0.4 0.40 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 . 1 2 0 0 0 0 1
Acute lymphoblastic acute A Ac Acu Acut BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 10 0 0 0 0 1
18 (20.5%) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (.) 3 3 0 0 0 0 1
8 (26.7%) 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 3 (.) 3 3 0 0 0 0 1
26 (22.0%) 26 2 26 26 26 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 3 (.) 3 3 0 0 0 0 1
Aplastic anemia aplastic A Ap Apl Apla BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 10 0 0 0 0 1
7 (8.0%) 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 4 (.) 3 5 0 0 0 0 1
5 (16.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 4 (.) 3 6 0 0 0 0 1
12 (10.2%) 12 1 12 12 12 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 6 0 0 0 0 1
Myelodysplastic syndrome myelodysplastic M My Mye Myel BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 10 0 0 0 0 1
18 (20.5%) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 4 0 0 0 0 1
4 (13.3%) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 4 (.) 3 4 0 0 0 0 1
22 (18.6%) 22 2 22 22 22 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 4 0 0 0 0 1
Transplant status, transplant T Tr Tra Tran BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,() 3 10 0 0 0 0 1
Pre-transplant Pre-transplant pre-transplant P Pr Pre Pre- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 - 1 10 0 0 0 0 1
27 (30.7%) 27 2 27 27 27 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 7 0 0 0 0 1
10 (33.3%) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 7 0 0 0 0 1
37 (31.4%) 37 3 37 37 37 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 7 0 0 0 0 1
0.07 0.07 0.07 0 0. 0.0 0.07 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 . 1 3 0 0 0 0 1
0.822 0.822 0.822 0 0. 0.8 0.82 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 . 1 4 0 0 0 0 1
Post-transplant Post-transplant post-transplant P Po Pos Post BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 - 1 10 0 0 0 0 1
61 (69.3%) 61 6 61 61 61 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 6 0 0 0 0 1
20 (66.5%) 20 2 20 20 20 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 6 0 0 0 0 1
81 (68.6%) 81 8 81 81 81 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 6 0 0 0 0 1
Infection sites, infection I In Inf Infe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 ,() 3 10 0 0 0 0 1
Pulmonary Pulmonary pulmonary P Pu Pul Pulm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 9 0 0 0 0 1
51 (58.0%) 51 5 51 51 51 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 10 0 0 0 0 1
18 (60.0%) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 10 0 0 0 0 1
69 (58.5%) 69 6 69 69 69 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 10 0 0 0 0 1
1.15 1.15 1.15 1 1. 1.1 1.15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 . 1 4 0 0 0 0 1
0.764 0.764 0.764 0 0. 0.7 0.76 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 . 1 5 0 0 0 0 1
Bloodstream Bloodstream bloodstream B Bl Blo Bloo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 10 0 0 0 0 1
33 (37.5%) 33 3 33 33 33 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 9 0 0 0 0 1
14 (46.7%) 14 1 14 14 14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 9 0 0 0 0 1
47 (39.8%) 47 4 47 47 47 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 9 0 0 0 0 1
Intestinal Intestinal intestinal I In Int Inte BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 10 0 0 0 0 1
13 (14.8%) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 10 0 0 0 0 1
5 (16.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 6 (.) 3 9 0 0 0 0 1
18 (15.3%) 18 1 18 18 18 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 10 0 0 0 0 1
C 2 c C C C C BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 6 no 0 10 0 0 0 0 1
13 (14.8%) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 5 0 0 0 0 1
8 (33.3%) 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 6 (.) 3 5 0 0 0 0 1
21 (17.8%) 21 2 21 21 21 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 5 0 0 0 0 1
CROs, n cros, C CR CRO CROs BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 ,() 3 10 0 0 0 0 1
CRKP CRKP crkp C CR CRK CRKP BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 4 0 0 0 0 1
21 (23.9%) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
12 (40.0%) 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
33 (28.0%) 33 3 33 33 33 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
2.96 2.96 2.96 2 2. 2.9 2.96 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 7 . 1 4 0 0 0 0 1
0.085 0.085 0.085 0 0. 0.0 0.08 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 7 . 1 5 0 0 0 0 1
CRAB CRAB crab C CR CRA CRAB BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 4 0 0 0 0 1
23 (26.1%) 23 2 23 23 23 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
7 (23.3%) 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 (.) 3 9 0 0 0 0 1
30 (25.4%) 30 3 30 30 30 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
CRPA CRPA crpa C CR CRP CRPA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 4 0 0 0 0 1
21 (23.9%) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
3 (10.0%) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 9 0 0 0 0 1
24 (20.3%) 24 2 24 24 24 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
Other CREs other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
31 (35.2%) 31 3 31 31 31 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
8 (26.7%) 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 9 0 0 0 0 1
39 (33.1%) 39 3 39 39 39 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
C 2 c C C C C BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
34 (38.6%) 34 3 34 34 34 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 6 0 0 0 0 1
5 (16.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 5 0 0 0 0 1
39 (33.1%) 39 3 39 39 39 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 6 0 0 0 0 1
Highly suspected highly H Hi Hig High BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
7 (8.0%) 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 9 (.) 3 4 0 0 0 0 1
5 (16.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 9 (.) 3 4 0 0 0 0 1
12 (10.2%) 12 1 12 12 12 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 5 0 0 0 0 1
Colistin sulfate colistin C Co Col Coli BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
Loading dose, loading L Lo Loa Load BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 ,() 3 10 0 0 0 0 1
5 (5.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 4 0 0 0 0 1
4 (13.3%) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 5 0 0 0 0 1
9 (7.6%) 9 9 9 9 9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 4 0 0 0 0 1
0.229 0.229 0.229 0 0. 0.2 0.22 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 . 1 3 0 0 0 0 1
Daily dose, daily D Da Dai Dail BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 10 ,() 3 10 0 0 0 0 1
1.0 million 1.0 1 1. 1.0 1.0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 ./ 2 10 0 0 0 0 1
30 (34.1%) 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 0 0 0 1
17 (56.7%) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 0 0 0 1
47(39.8%) 47(39.8%) 47(39.8%) 4 47 47( 47(3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 0 0 0 1
4.76 4.76 4.76 4 4. 4.7 4.76 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 . 1 2 0 0 0 0 1
0.029 0.029 0.029 0 0. 0.0 0.02 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 . 1 3 0 0 0 0 1
1.5 million 1.5 1 1. 1.5 1.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 ./ 2 10 0 1 0 0 1
58 (65.9%) 58 5 58 58 58 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 1 0 0 1
13 (43.3%) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 1 0 0 1
71 (60.2%) 71 7 71 71 71 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 1 0 0 1
Cumulative dose, cumulative C Cu Cum Cumu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 , 1 10 0 1 0 0 1
(mean ± (mean ( (m (me (mea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 () 2 4 0 1 0 0 1
18.58 ± 18.58 1 18 18. 18.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .. 2 9 0 1 0 0 1
14.67 ± 14.67 1 14 14. 14.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .. 2 10 0 1 0 0 1
17.58 ± 17.58 1 17 17. 17.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .. 2 9 0 1 0 0 1
2.160 2.160 2.160 2 2. 2.1 2.16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 . 1 4 0 1 0 0 1
0.033 0.033 0.033 0 0. 0.0 0.03 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 . 1 4 0 1 0 0 1
146 146 146 1 14 146 146 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 11 no 0 1 0 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 ():- 4 10 0 1 1 0 0
with different with w wi wit with BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
one or one o on one one BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
that of that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
not when not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
agents (Fig. agents a ag age agen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 (.). 4 3 0 0 0 0 1
Of the of O Of Of Of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
results, 77 results, r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,(.) 4 9 0 0 0 0 1
causative microorganism, causative c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,(.) 4 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 (.) 3 8 0 0 0 0 1
ineffective group. ineffective i in ine inef BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 0 0 0 1
group, patients group, g gr gro grou BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 10 0 0 0 0 1
had a had h ha had had BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
rate (p rate r ra rat rate BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 (.). 4 3 0 0 0 0 1
Analysis of analysis A An Ana Anal BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
The changes the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 - 1 8 0 0 0 0 1
ated before ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 . 1 9 0 0 0 0 1
Overall, all overall, O Ov Ove Over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 ,-- 3 9 0 0 0 0 1
ated indicators ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 no 0 8 0 0 0 0 1
sulfate treatment, sulfate s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 , 1 8 0 0 0 0 1
platelet levels platelet p pl pla plat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 2 (.), 4 10 0 0 0 0 1
and C-reaction and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 -() 3 9 0 0 0 0 1
(PCT) levels (pct) ( (P (PC (PCT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 ()(.). 6 9 0 0 0 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 10 0 1 0 0 1
Characteristics Characteristics characteristics C Ch Cha Char BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 0 1 0 0 1
Effective group effective E Ef Eff Effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 () 2 5 0 1 0 0 1
Ineffective group ineffective I In Ine Inef BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 () 2 5 0 1 0 0 1
Total Total total T To Tot Tota BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 6 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 () 2 10 0 1 0 0 1
t/v 2 t/v t t/ t/v t/v BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 / 1 10 0 1 0 0 1
value value value v va val valu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 0 1 0 0 1
p-value p-value p-value p p- p-v p-va BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 - 1 10 0 1 0 0 1
Treatment duration, treatment T Tr Tre Trea BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 10 0 1 0 0 1
(mean ± (mean ( (m (me (mea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 () 2 4 0 1 0 0 1
13.73 ± 13.73 1 13 13. 13.7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .. 2 10 0 1 0 0 1
9.90 ± 9.90 9 9. 9.9 9.90 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .. 2 9 0 1 0 0 1
12.75 ± 12.75 1 12 12. 12.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .. 2 10 0 1 0 0 1
3.18 3.18 3.18 3 3. 3.1 3.18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 . 1 3 0 1 0 0 1
0.002 0.002 0.002 0 0. 0.0 0.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 . 1 4 0 1 0 0 1
Treatment course, treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 ,() 3 10 0 0 0 0 1
B 7 b B B B B BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 5 no 0 8 0 0 0 0 1
10 (11.4%) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 5 (.) 3 10 0 0 0 0 1
11 (36.7%) 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 5 (.) 3 10 0 0 0 0 1
21 (17.8%) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 5 (.) 3 10 0 0 0 0 1
10.77 10.77 10.77 1 10 10. 10.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 . 1 5 0 0 0 0 1
0.005 0.005 0.005 0 0. 0.0 0.00 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 . 1 5 0 0 0 0 1
8-14 days 8-14 8 8- 8-1 8-14 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 6 - 1 9 0 0 0 0 1
47 (53.4%) 47 4 47 47 47 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
14 (46.7%) 14 1 14 14 14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
61 (51.7%) 61 6 61 61 61 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
[ 14 [ [ [ [ [ BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 6 [ 1 9 0 0 0 0 1
31 (35.2%) 31 3 31 31 31 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
5 (16.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 6 (.) 3 9 0 0 0 0 1
36 (30.5%) 36 3 36 36 36 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
Antibacterial combination antibacterial A An Ant Anti BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 6 ,()* 4 10 0 0 0 0 1
Colistin sulfate colistin C Co Col Coli BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
3 (3.4%) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 7 (.) 3 3 0 0 0 0 1
6 (20.0%) 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 7 (.) 3 3 0 0 0 0 1
9 (7.6%) 9 9 9 9 9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 7 (.) 3 3 0 0 0 0 1
10.33 10.33 10.33 1 10 10. 10.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 . 1 2 0 0 0 0 1
0.016 0.016 0.016 0 0. 0.0 0.01 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 . 1 2 0 0 0 0 1
Combined one combined C Co Com Comb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
8 (26.7%) 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 7 (.) 3 2 0 0 0 0 1
40 (33.9%) 40 4 40 40 40 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 2 0 0 0 0 1
Combined 2 combined C Co Com Comb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
44 (50%) 44 4 44 44 44 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 () 2 2 0 0 0 0 1
11 (36.7%) 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 3 0 0 0 0 1
55 (46.6%) 55 5 55 55 55 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 3 0 0 0 0 1
Combined C combined C Co Com Comb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
agents agents agents a ag age agen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 2 0 0 0 0 1
9 (10.2%) 9 9 9 9 9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 8 (.) 3 9 0 0 0 0 1
5 (16.6%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 8 (.) 3 9 0 0 0 0 1
14 (11.9%) 14 1 14 14 14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 8 (.) 3 10 0 0 0 0 1
Outcome Outcome outcome O Ou Out Outc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
Bacteria eradication bacteria B Ba Bac Bact BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
72 (88.9%) 72 7 72 72 72 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 8 (.) 3 5 0 0 0 0 1
5 (20.0%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 8 (.) 3 4 0 0 0 0 1
77 (72.6%) 77 7 77 77 77 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 8 (.) 3 6 0 0 0 0 1
41.89 41.89 41.89 4 41 41. 41.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 . 1 2 0 0 0 0 1
\ 0.001 \ \ \ \ \ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 5 8 . 1 3 0 0 0 0 1
Nephrotoxicity Nephrotoxicity nephrotoxicity N Ne Nep Neph BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
5 (5.7%) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
4 (13.3%) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
9 (7.6%) 9 9 9 9 9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
0.221 0.221 0.221 0 0. 0.2 0.22 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 . 1 4 0 0 0 0 1
Neurotoxicity Neurotoxicity neurotoxicity N Ne Neu Neur BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
1 (1.1%) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
2 (6.7%) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
3 (2.5%) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 9 (.) 3 6 0 0 0 0 1
0.159 0.159 0.159 0 0. 0.1 0.15 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 . 1 4 0 0 0 0 1
SD Standard sd S SD SD SD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ;-;-; 5 9 0 0 0 0 1
carbapenem-resistant Klebsiella carbapenem-resistant c ca car carb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 -;-;- 5 9 0 0 0 0 1
resistant Enterobacteriaceae; resistant r re res resi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 ; 1 4 0 0 0 0 1
*Antibacterial agents *antibacterial * *A *An *Ant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 *,,,- 5 10 0 0 0 0 1
fomycin, tigecycline, fomycin, f fo fom fomy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 ,,,. 4 3 0 0 0 0 1
v 2 v v v v v BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 10 - 1 0 0 0 0 0 1
à Twelve à à à à à BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 10 no 0 9 0 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 ():- 4 10 0 1 1 0 0
147 147 147 1 14 147 147 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 11 no 0 1 0 1 0 0 0
Compared to compared C Co Com Comp BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 9 1 0 0 0 1
(Cr) was (cr) ( (C (Cr (Cr) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ()- 3 9 1 0 0 0 1
istration, suggesting istration, i is ist istr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,- 2 10 1 0 0 0 1
ment might ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ., 2 8 1 0 0 0 1
the level the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 (), 3 9 1 0 0 0 1
aspartate aminotransferase aspartate a as asp aspa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (), 3 8 1 0 0 0 1
bilirubin (TBIL) bilirubin b bi bil bili BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (), 3 9 1 0 0 0 1
suggesting that suggesting s su sug sugg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 1 0 0 0 1
liver function liver l li liv live BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ([.)(.). 8 7 1 0 0 0 1
Factors Associated factors F Fa Fac Fact BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 1 no 0 10 0 0 0 0 1
Multivariate logistic multivariate M Mu Mul Mult BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 2 no 0 9 0 0 0 0 1
analyze all analyze a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 - 1 9 0 0 0 0 1
cant differences cant c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 9 0 0 0 0 1
colistin treatment colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 . 1 8 0 0 0 0 1
course (p course c co cou cour BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 (.;.; 5 7 0 0 0 0 1
1.107-8.019) and 1.107-8.019) 1 1. 1.1 1.10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 .-.) 4 8 0 0 0 0 1
antibacterial agents antibacterial a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 (.;.; 5 9 0 0 0 0 1
95% CI 95% 9 95 95% 95% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 .-.) 4 10 0 0 0 0 1
were significantly were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 10 0 0 0 0 1
effectiveness of effectiveness e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 . 1 10 0 0 0 0 1
that the that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 9 0 0 0 0 1
and co-medication and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 - 1 8 0 0 0 0 1
agents, rather agents, a ag age agen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 , 1 9 0 0 0 0 1
sulfate and sulfate s su sul sulf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 10 1 0 0 0 1
curative effect curative c cu cur cura BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 (.). 4 5 1 0 0 0 1
Mortality Analysis mortality M Mo Mor Mort BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 10 0 0 0 0 1
Twenty-seven patients twenty-seven T Tw Twe Twen BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 -, 2 9 0 0 0 0 1
with an with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -- 2 9 0 0 0 0 1
22.9%. Compared 22.9%. 2 22 22. 22.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .., 3 8 0 0 0 0 1
patients in patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 10 0 0 0 0 1
significantly lower significantly s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -(.. 4 10 0 0 0 0 1
66.7%, v 66.7%, 6 66 66. 66.7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 .,.,.)(.). 10 8 0 0 0 0 1
Safety Evaluation safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
Overall, nephrotoxicity overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 , 1 9 0 0 0 0 1
(7.6%) cases (7.6%) ( (7 (7. (7.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 (.) 3 9 0 0 0 0 1
(2.5%). The (2.5%). ( (2 (2. (2.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 (.). 4 9 0 0 0 0 1
was comparable was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 9 0 0 0 0 1
and ineffective and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 , 1 8 0 0 0 0 1
nephrotoxicity of nephrotoxicity n ne nep neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 ..(.) 5 9 0 0 0 0 1
and neurotoxicity and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 .. 2 7 0 0 0 0 1
(p = (p ( (p (p (p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 (.),(). 7 9 0 0 0 0 1
patients developed patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 8 0 0 0 0 1
4-7 days 4-7 4 4- 4-7 4-7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 7 -, 2 9 0 0 0 0 1
seven patients seven s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
creatinine after creatinine c cr cre crea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 no 0 9 0 0 0 0 1
Fig. 2 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 10 1 0 0 0 1
different treatment different d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 8 1 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 9 1 0 0 0 1
combinations. Antibacterial combinations. c co com comb BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 9 1 0 0 0 1
with colistin with w wi wit with BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 ,- 2 9 1 0 0 0 1
sides, quinolones, sides, s si sid side BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 ,,,,,. 6 10 1 0 0 0 1
*p \ *p * *p *p *p BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 10 *.;**.; 7 9 1 0 0 0 1
148 148 148 1 14 148 148 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 1 1 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 11 ():- 4 10 1 1 1 0 0
sulfate and sulfate s su sul sulf BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 1 1 0 0 1
failure caused failure f fa fai fail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 1 1 0 0 1
with neurotoxicity with w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 1 1 0 0 1
discontinuation of discontinuation d di dis disc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 1 ( 1 9 1 1 0 0 1
in Table in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 1 ). 2 10 1 1 0 0 1
safe and safe s sa saf safe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 . 1 5 1 1 0 0 1
Fig. 3 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 3 . 1 8 1 0 0 0 1
baseline and baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 .: 2 10 1 0 0 0 1
before colistin before b be bef befo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ;: 2 9 1 0 0 0 1
after colistin after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ;; 2 9 1 0 0 0 1
ALT ALT alt A AL ALT ALT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 3 no 0 0 1 0 0 0 1
alanine alanine alanine a al ala alan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 no 0 1 1 0 0 0 1
aminotransferase; AST aminotransferase; a am ami amin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 ; 1 3 1 0 0 0 1
aspartate aspartate aspartate a as asp aspa BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 no 0 1 1 0 0 0 1
aminotransferase; Cr aminotransferase; a am ami amin BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 6 ;;-; 4 10 1 0 0 0 1
PLT platelet; plt P PL PLT PLT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 ;;. 3 9 1 0 0 0 1
Data were data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 .*.; 4 7 1 0 0 0 1
**p \ **p * ** **p **p BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 6 **.; 4 8 1 0 0 0 1
Fig. 4 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 10 1 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 11 ():- 4 10 1 1 1 0 0
149 149 149 1 14 149 149 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 1 1 1 0 0 0
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 10 1 0 0 0 1
In this in I In In In BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
with CRO with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 10 1 0 0 0 1
were retrospectively were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 8 1 0 0 0 1
product sheet's product p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 '.-. 4 8 1 0 0 0 1
million IU million m mi mil mill BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 9 1 0 0 0 1
terial clearance terial t te ter teri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 . 1 8 1 0 0 0 1
65.3%, respectively, 65.3%, 6 65 65. 65.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .,,- 4 8 1 0 0 0 1
tiveness over tiveness t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 - 1 9 1 0 0 0 1
spective studies spective s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .(, 3 9 1 0 0 0 1
respectively) and respectively) r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ).(.., 6 9 1 0 0 0 1
respectively) [29]. respectively) r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 )[]., 5 10 1 0 0 0 1
population, approximately population, p po pop popu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
had pulmonary had h ha had had BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
patients received patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 1 0 0 0 1
Effective antibiotic effective E Ef Eff Effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
infections requires infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 1 0 0 0 1
the infection the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 1 0 0 0 1
exceed the exceed e ex exc exce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
(MIC) to (mic) ( (M (MI (MIC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 () 2 9 1 0 0 0 1
strain. Although strain. s st str stra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .- 2 9 1 0 0 0 1
istin sulfate istin i is ist isti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
unknown, and unknown, u un unk unkn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
efficacy in efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
unclear, it unclear, u un unc uncl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
efficacy when efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
intravenous infusion intravenous i in int intr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 9 1 0 0 0 1
ering that ering e er eri erin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 1 0 0 0 1
into tissues into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 1 0 0 0 1
into the into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 []. 3 5 1 0 0 0 1
In addition, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 0 , 1 7 1 0 0 0 1
patients with patients p pa pat pati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
treatment with treatment t tr tre trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 7 0 0 0 0 1
or [ or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 [ 1 9 0 0 0 0 1
than those than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 -( 2 8 0 0 0 0 1
p \ p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 7 4 .);, 4 8 0 0 0 0 1
duration to duration d du dur dura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 [ 1 9 0 0 0 0 1
increase in increase i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 9 0 0 0 0 1
for 8-14 for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 -([.)[]. 8 9 0 0 0 0 1
study are study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 9 0 0 0 0 1
Extending the extending E Ex Ext Exte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
sulfate to sulfate s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 10 0 0 0 0 1
efficacy than efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 8 0 0 0 0 1
Although a although A Al Alt Alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 4 [ 1 9 0 0 0 0 1
showed better showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 , 1 9 0 0 0 0 1
duration confers duration d du dur dura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 9 0 0 0 0 1
efit compared efit e ef efi efit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 -., 3 9 0 0 0 0 1
prior studies prior p pr pri prio BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
polymyxin treatment polymyxin p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
cal patients cal c ca cal cal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 4 . 1 9 0 0 0 0 1
Therefore, the therefore, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 4 , 1 8 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 no 0 9 0 0 0 0 1
diseases remains diseases d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
further investigated. further f fu fur furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 4 0 0 0 0 1
Heterogeneous resistance heterogeneous H He Het Hete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
ins has ins i in ins ins BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 ,,[]. 5 8 0 0 0 0 1
However, the however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 4 , 1 9 0 0 0 0 1
can be can c ca can can BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
bination of bination b bi bin bina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
bials [32-34]. bials b bi bia bial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 [-].,. 6 9 0 0 0 0 1
were treated were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
with one with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 , 1 8 0 0 0 0 1
clinical response clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 8 0 0 0 0 1
these patients. these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 9 0 0 0 0 1
the results the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 9 0 0 0 0 1
bination therapy bination b bi bin bina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 8 0 0 0 0 1
apy [35-37]. apy a ap apy apy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 [-].,, 6 9 0 0 0 0 1
a small a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 4 (/) 3 9 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 ,- 2 8 0 0 0 0 1
sponding results sponding s sp spo spon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
size, which size, s si siz size BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 ,. 2 8 0 0 0 0 1
In the in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 4 , 1 9 0 0 0 0 1
dose of dose d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 - 1 9 0 0 0 0 1
cacy, but cacy, c ca cac cacy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 , 1 9 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
affecting the affecting a af aff affe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 , 1 9 0 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 8 0 0 0 0 1
High post-treatment high H Hi Hig High BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 4 - 1 7 0 0 0 0 1
indicated poor indicated i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 4 . 1 10 0 0 0 0 1
CRP and crp C CR CRP CRP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 4 - 1 9 0 0 0 0 1
entiating bacterial entiating e en ent enti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 4 no 0 8 0 0 0 0 1
Fig. 5 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 .- 2 10 1 0 0 0 1
following treatment following f fo fol foll BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 11 no 0 7 1 0 0 0 1
150 150 150 1 15 150 150 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 11 no 0 1 1 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 ():- 4 10 1 1 1 0 0
inflammation and inflammation i in inf infl BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 [-]. 4 8 0 0 0 0 1
The present the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
decrease in decrease d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
treatment with treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
of therapeutic of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 (),- 4 7 0 0 0 0 1
treatment CRP treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 7 0 0 0 0 1
assess the assess a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
therapy and therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
therapy. In therapy. t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,- 3 8 0 0 0 0 1
let counts let l le let let BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 7 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 8 0 0 0 0 1
the increase the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
treatment contributes treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -. 2 9 0 0 0 0 1
In terms in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 0 ,- 2 8 0 0 0 0 1
dence of dence d de den denc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
In this in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 0 ,. 2 8 0 0 0 0 1
mild nephrotoxicity, mild m mi mil mild BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,., 3 8 0 0 0 0 1
and no and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 7 0 0 0 0 1
Studies have studies S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
limiting for limiting l li lim limi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 [,,]. 5 9 0 0 0 0 1
meta-analyses showed meta-analyses m me met meta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -- 2 7 0 0 0 0 1
dences of dences d de den denc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 --- 3 7 0 0 0 0 1
city were city c ci cit city BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,[,]. 6 8 0 0 0 0 1
Compared with compared C Co Com Comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
the event the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ( 1 8 0 0 0 0 1
9.2%) [21, 9.2%) 9 9. 9.2 9.2% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 .)[,]., 7 8 0 0 0 0 1
B, we b, B B, B, B, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 []. 3 8 0 0 0 0 1
findings, we findings, f fi fin find BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
colistin sulfate colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 . 1 10 0 0 0 0 1
However, this however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 ,. 2 8 0 0 0 0 1
First, this first, F Fi Fir Firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 9 0 0 0 0 1
with limited with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 7 0 0 0 0 1
concentrations of concentrations c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
monitored during monitored m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,/ 2 7 0 0 0 0 1
analysis was analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 8 0 0 0 0 1
decisions about decisions d de dec deci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,, 2 8 0 0 0 0 1
duration based duration d du dur dura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 7 0 0 0 0 1
clinical experience, clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
identify the identify i id ide iden BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 7 0 0 0 0 1
tions. Third, tions. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 8 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
other drugs, other o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
solely responsible solely s so sol sole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
Moreover, in moreover, M Mo Mor More BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 ,, 2 8 0 0 0 0 1
fraction of fraction f fr fra frac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 (.) 3 9 0 0 0 0 1
but did but b bu but but BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
therapy, which therapy, t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 8 0 0 0 0 1
crobial treatment crobial c cr cro crob BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 7 0 0 0 0 1
prospective, multicenter, prospective, p pr pro pros BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ,,- 3 7 0 1 0 0 1
trolled, and trolled, t tr tro trol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ,- 2 9 0 1 0 0 1
better evaluate better b be bet bett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 10 0 1 0 0 1
sulfate in sulfate s su sul sulf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 . 1 4 0 1 0 0 1
CONCLUSIONS CONCLUSIONS conclusions C CO CON CONC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
As one as A As As As BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
been marketed been b be bee been BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 8 0 0 0 0 1
an increasingly an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
of CRO of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 . 1 8 0 0 0 0 1
clarify the clarify c cl cla clar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
in hematological in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
and such and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
current literature current c cu cur curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
ence for ence e en enc ence BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 . 1 9 0 0 0 0 1
the study the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 , 1 8 0 0 0 0 1
effective antimicrobial effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
tions. Furthermore, tions. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 ., 2 8 0 0 0 0 1
treatment course treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 8 0 0 0 0 1
combination with combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 8 0 0 0 0 1
were the were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
colistin sulfate. colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 .- 2 9 0 0 0 0 1
dence of dence d de den denc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 , 1 8 0 0 0 0 1
which provides which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
use of use u us use use BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 . 1 8 0 0 0 0 1
Author Contribution. author A Au Aut Auth BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 . 1 7 0 0 0 0 1
Xiaohui Hu xiaohui X Xi Xia Xiao BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 ;- 2 9 0 0 0 0 1
vided administrative vided v vi vid vide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 9 ;- 2 9 0 0 0 0 1
vided the vided v vi vid vide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 9 ; 1 8 0 0 0 0 1
Shanshan Jiang, shanshan S Sh Sha Shan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 ,,, 3 9 0 0 0 0 1
Li, Xing li, L Li Li, Li, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 ,,, 3 9 0 0 0 0 1
the data; the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 ; 1 8 0 0 0 0 1
performed the performed p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 ; 1 10 0 0 0 0 1
Yuanbing Wu yuanbing Y Yu Yua Yuan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 9 . 1 9 0 0 0 0 1
reviewed the reviewed r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 9 0 0 0 0 1
version. version. version. v ve ver vers BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 . 1 1 0 0 0 0 1
Funding. The funding. F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 10 . 1 7 0 0 0 0 1
grants from grants g gr gra gran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 no 0 9 0 0 0 0 1
Yuan Da yuan Y Yu Yua Yuan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 10 no 0 8 0 0 0 0 1
(H221084); Innovative (h221084); ( (H (H2 (H22 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 10 (); 3 9 0 0 0 0 1
Research Project research R Re Res Rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 8 10 - 1 10 0 0 0 0 1
ical Specialists ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 10 ().' 4 9 0 0 0 0 1
Rapid Service rapid R Ra Rap Rapi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 10 - 1 9 0 0 0 0 1
tal of tal t ta tal tal BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 10 . 1 6 0 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 ():- 4 10 0 1 1 0 0
151 151 151 1 15 151 151 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 11 no 0 1 0 1 0 0 0
Data Availability. data D Da Dat Data BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 9 0 1 0 0 1
during and/or during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 / 1 9 0 1 0 0 1
study are study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 1
author on author a au aut auth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 6 0 1 0 0 1
Declarations Declarations declarations D De Dec Decl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 1
Conflict of conflict C Co Con Conf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 .,- 3 9 0 0 0 0 1
shan Jiang, shan s sh sha shan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 8 0 ,,,, 4 10 0 0 0 0 1
Xing Wang, xing X Xi Xin Xing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,, 4 9 0 0 0 0 1
and Xiaohui and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
interests. interests. interests. i in int inte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 2 0 0 0 0 1
Ethical Approval. ethical E Et Eth Ethi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 . 1 8 0 0 0 0 1
was performed was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 1 - 1 9 0 0 0 0 1
gci Hematology, gci g gc gci gci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 1 ,,, 3 8 0 0 0 0 1
China. This china. C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 . 1 9 0 0 0 0 1
Committee of committee C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 no 0 8 0 0 0 0 1
Hematology and hematology H He Hem Hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 no 0 8 0 0 0 0 1
consent because consent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 1 . 1 9 0 0 0 0 1
Furthermore, the furthermore, F Fu Fur Furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 , 1 8 0 0 0 0 1
accordance with accordance a ac acc acco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 1 ( 1 10 0 0 0 0 1
revised in revised r re rev revi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 1 ). 2 3 0 0 0 0 1
Open Access. open O Op Ope Open BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 9 0 0 0 0 1
Creative Commons creative C Cr Cre Crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 -- 2 7 0 0 0 0 1
cial 4.0 cial c ci cia cial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 2 ., 2 9 0 0 0 0 1
any non-commercial any a an any any BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 -,,, 4 9 0 0 0 0 1
distribution and distribution d di dis dist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 8 0 0 0 0 1
or format, or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 , 1 10 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 (), 3 10 0 0 0 0 1
a link a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 9 2 , 1 8 0 0 0 0 1
indicate if indicate i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 9 0 0 0 0 1
other third other o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
included in included i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ' 1 8 0 0 0 0 1
licence, unless licence, l li lic lice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 , 1 9 0 0 0 0 1
line to line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 10 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 2 ' 1 9 0 0 0 0 1
your intended your y yo you your BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
regulation or regulation r re reg regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 , 1 9 0 0 0 0 1
will need will w wi wil will BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 2 no 0 9 0 0 0 0 1
copyright holder. copyright c co cop copy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ., 2 10 0 0 0 0 1
visit http://creativecommons.org/licenses/by- visit v vi vis visi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ://.//- 7 9 0 0 0 0 1
nc/4.0/. nc/4.0/. nc/4.0/. n nc nc/ nc/4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 2 /./. 4 1 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 no 0 10 0 1 0 0 1
1. Averbuch 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 4 .,,,. 5 10 0 0 0 0 1
resistance in resistance r re res resi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 -- 2 8 0 0 0 0 1
teremia in teremia t te ter tere BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 no 0 8 0 0 0 0 1
recipients: intercontinental recipients: r re rec reci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 : 1 9 0 0 0 0 1
infectious diseases infectious i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 no 0 8 0 0 0 0 1
bone marrow bone b bo bon bone BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 4 . 1 8 0 0 0 0 1
Dis. 2017;65(11):1819-28. dis. D Di Dis Dis. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 4 .;():-. 7 4 0 0 0 0 1
2. Zeng 2. 2 2. 2. 2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,. 5 10 0 0 0 0 1
diagnosis, treatment, diagnosis, d di dia diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
infections caused infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 -- 2 9 0 0 0 0 1
negative bacilli. negative n ne neg nega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 .. 2 8 0 0 0 0 1
2023;S1684-1182(23):00036-41. 2023;S1684-1182(23):00036-41. 2023;s1684-1182(23):00036-41. 2 20 202 2023 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 5 ;-():-. 7 5 0 0 0 0 1
3. Loon 3. 3 3. 3. 3. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 6 .,',. 5 10 0 0 0 0 1
review and review r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 -- 2 9 0 0 0 0 1
ology of ology o ol olo olog BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 -. 2 9 0 0 0 0 1
Antimicrob Agents antimicrob A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 .;():- 6 8 0 0 0 0 1
e11717. e11717. e11717. e e1 e11 e117 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 6 . 1 1 0 0 0 0 1
4. Micozzi 4. 4 4. 4. 4. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,,,.- 6 10 0 0 0 0 1
resistant Klebsiella resistant r re res resi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 -- 2 9 0 0 0 0 1
tological patients: tological t to tol tolo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 :, 2 9 0 0 0 0 1
factors and factors f fa fac fact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 -- 2 9 0 0 0 0 1
siella pneumoniae siella s si sie siel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 .. 2 8 0 0 0 0 1
2017;17(1):203. 2017;17(1):203. 2017;17(1):203. 2 20 201 2017 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 7 ;():. 5 2 0 0 0 0 1
5. Satlin 5. 5 5. 5. 5. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 8 .,,.- 5 10 0 0 0 0 1
lenge of lenge l le len leng BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 - 1 9 0 0 0 0 1
in transplant in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 8 - 1 9 0 0 0 0 1
logic malignancies. logic l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 ..;(): 6 9 0 0 0 0 1
1274-83. 1274-83. 1274-83. 1 12 127 1274 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 8 -. 2 1 0 0 0 0 1
6. Satlin 6. 6 6. 6. 6. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 8 .,,,. 5 10 0 0 0 0 1
carbapenem-resistant Enterobacteriaceae carbapenem-resistant c ca car carb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 -- 2 8 0 0 0 0 1
tropenic patients tropenic t tr tro trop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 . 1 8 0 0 0 0 1
J Infect. j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 9 8 .;():-. 7 5 0 0 0 0 1
7. Andria 7. 7 7. 7. 7. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 9 .,,,. 5 10 0 0 0 0 1
related to related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 - 1 8 0 0 0 0 1
Gram-negative bacteria gram-negative G Gr Gra Gram BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 - 1 7 0 0 0 0 1
cancer patients: cancer c ca can canc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 :. 2 8 0 0 0 0 1
J Antimicrob j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 9 9 .;():-. 7 8 0 0 0 0 1
8. Lalaoui 8. 8 8. 8. 8. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 10 .,,,. 5 10 0 0 0 0 1
to carbapenem-resistant to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 - 1 8 0 0 0 0 1
hematologic malignancies. hematologic h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 .. 2 7 0 0 0 0 1
2020;11:1422. 2020;11:1422. 2020;11:1422. 2 20 202 2020 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 10 ;:. 3 2 0 0 0 0 1
9. Jaiswal 9. 9 9. 9. 9. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 10 .,,,.- 6 10 0 0 0 0 1
tion with tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 - 1 9 0 0 0 0 1
adversely impacts adversely a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 no 0 8 0 0 0 0 1
hematological malignancies: hematological h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 :- 2 9 0 0 0 0 1
tive surveillance tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 10 . 1 9 0 0 0 0 1
Dis. 2018;10(1): dis. D Di Dis Dis. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 10 .;():. 6 5 0 0 0 0 1
10. Adukauskiene 10. 1 10 10. 10. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 11 .,,, 4 10 0 1 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 11 .- 2 9 0 1 0 0 1
terial and terial t te ter teri BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 11 - 1 9 0 1 0 0 1
152 152 152 1 15 152 152 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 11 no 0 1 0 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 ():- 4 10 0 1 1 0 0
associated pneumonia associated a as ass asso BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 10 0 1 0 0 1
Acinetobacter Acinetobacter acinetobacter A Ac Aci Acin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 2 0 1 0 0 1
baumannii. baumannii. baumannii. b ba bau baum BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 2 0 1 0 0 1
Antibiotics Antibiotics antibiotics A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 2 0 1 0 0 1
(Basel). (Basel). (basel). ( (B (Ba (Bas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 (). 3 1 0 1 0 0 1
2022;11(7):892. 2022;11(7):892. 2022;11(7):892. 2 20 202 2022 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;():. 5 3 0 1 0 0 1
11. Tsuji 11. 1 11 11. 11. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,,,. 5 10 0 0 0 0 1
consensus guidelines consensus c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
polymyxins: endorsed polymyxins: p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 : 1 8 0 0 0 0 1
clinical pharmacy clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 (), 3 7 0 0 0 0 1
clinical microbiology clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 (- 2 8 0 0 0 0 1
MID), infectious mid), M MI MID MID) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ),(), 5 9 0 0 0 0 1
international society international i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -- 2 8 0 0 0 0 1
ogy (ISAP), ogy o og ogy ogy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 (),(), 6 9 0 0 0 0 1
and society and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
(SIDP). Pharmacotherapy. (sidp). ( (S (SI (SID BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ()..;():-. 10 7 0 0 0 0 1
12. El-Sayed 12. 1 12 12. 12. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 1 .-,,,. 6 9 0 0 0 0 1
Colistin and colistin C Co Col Coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 1 - 1 10 0 0 0 0 1
tance: an tance: t ta tan tanc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 1 :(-). 5 8 0 0 0 0 1
Microbes Infect. microbes M Mi Mic Micr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 1 .;():-. 7 6 0 0 0 0 1
13. Sirijatuphat 13. 1 13 13. 13. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,,, 4 10 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 . 1 9 0 0 0 0 1
sitafloxacin for sitafloxacin s si sit sita BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 - 1 9 0 0 0 0 1
acinetobacter baumannii acinetobacter a ac aci acin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 : 1 9 0 0 0 0 1
study. Antibiotics study. s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 .().;():. 9 8 0 0 0 0 1
14. Zheng 14. 1 14 14. 14. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,,,./- 7 8 0 0 0 0 1
ibactam-based versus ibactam-based i ib iba ibac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 --- 3 8 0 0 0 0 1
tic regimens tic t ti tic tic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 - 1 7 0 0 0 0 1
resistant klebsiella resistant r re res resi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 - 1 8 0 0 0 0 1
cally ill cally c ca cal call BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 10 2 :. 2 10 0 0 0 0 1
Dis Ther. dis D Di Dis Dis BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 2 .;():-. 7 5 0 0 0 0 1
15. Xia 15. 1 15 15. 15. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,. 3 10 0 0 0 0 1
in carbapenem-resistant in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 3 -- 2 8 0 0 0 0 1
infections. BMC infections. i in inf infe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 ..;():. 7 7 0 0 0 0 1
16. Zhang 16. 1 16 16. 16. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,,,. 5 10 0 0 0 0 1
safety of safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 - 1 8 0 0 0 0 1
bapenem-resistant Gram-negative bapenem-resistant b ba bap bape BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 --- 3 8 0 0 0 0 1
tions: a tions: t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 :-.. 4 9 0 0 0 0 1
2021;19:431. 2021;19:431. 2021;19:431. 2 20 202 2021 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 3 ;:. 3 2 0 0 0 0 1
17. Yu 17. 1 17 17. 17. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 .,,,./- 7 10 0 0 0 0 1
macodynamics of macodynamics m ma mac maco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 no 0 8 0 0 0 0 1
bloodstream infection bloodstream b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 4 -- 2 8 0 0 0 0 1
sistant Klebsiella sistant s si sis sist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 .. 2 9 0 0 0 0 1
2022;13: 975066. 2022;13: 2 20 202 2022 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 4 ;:. 3 3 0 0 0 0 1
18. Wagenlehner 18. 1 18 18. 18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 .,,,.- 6 10 0 0 0 0 1
tematic review tematic t te tem tema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 no 0 9 0 0 0 0 1
and neurotoxicity and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 4 no 0 8 0 0 0 0 1
polymyxins. polymyxins. polymyxins. p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 . 1 2 0 0 0 0 1
Clin Clin clin C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 4 no 0 0 0 0 0 0 1
Microbiol Microbiol microbiol M Mi Mic Micr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 4 no 0 1 0 0 0 0 1
Infect. Infect. infect. I In Inf Infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 4 . 1 1 0 0 0 0 1
2021;S1198-743X(20):30764-73. 2021;S1198-743X(20):30764-73. 2021;s1198-743x(20):30764-73. 2 20 202 2021 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 4 ;-():-. 7 5 0 0 0 0 1
19. Zavascki 19. 1 19 19. 19. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,. 3 9 0 0 0 0 1
polymyxins: is polymyxins: p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :- 2 10 0 0 0 0 1
timethate and timethate t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ? 1 9 0 0 0 0 1
Chemother. 2017;61(3):e02319-e2416. chemother. C Ch Che Chem BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 .;():-. 7 7 0 0 0 0 1
20. Mattos 20. 2 20 20. 20. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,,,. 5 10 0 1 0 0 1
hyperpigmentation hyperpigmentation hyperpigmentation h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 no 0 3 0 1 0 0 1
following following following f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 1 0 1 0 0 1
intravenous intravenous intravenous i in int intr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 2 0 1 0 0 1
polymyxin B polymyxin p po pol poly BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 no 0 9 0 1 0 0 1
activation and activation a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 . 1 10 0 1 0 0 1
Ther. 2017;42(5):573-8. ther. T Th The Ther BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .;():-. 7 4 0 1 0 0 1
21. Xie 21. 2 21 21. 21. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,.- 6 9 0 1 0 0 1
cokinetics of cokinetics c co cok coki BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 no 0 8 0 1 0 0 1
dosage optimization dosage d do dos dosa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 . 1 10 0 1 0 0 1
Pharmacol. 2022;13: pharmacol. P Ph Pha Phar BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .;:. 4 5 0 1 0 0 1
22. Peng 22. 2 22 22. 22. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,. 5 10 0 0 0 0 1
of colistin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 no 0 9 0 0 0 0 1
caused by caused c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 -:- 3 8 0 0 0 0 1
ticenter retrospective ticenter t ti tic tice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 .. 2 9 0 0 0 0 1
2023;15(4):1794-804. 2023;15(4):1794-804. 2023;15(4):1794-804. 2 20 202 2023 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;():-. 6 3 0 0 0 0 1
23. Jin 23. 2 23 23. 23. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 7 .,,,. 5 10 0 0 0 0 1
nephrotoxicity of nephrotoxicity n ne nep neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 no 0 10 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 -- 2 8 0 0 0 0 1
bacterial infections: bacterial b ba bac bact BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 :. 2 9 0 0 0 0 1
Ann Transl ann A An Ann Ann BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 7 .;():. 6 6 0 0 0 0 1
24. Infectious 24. 2 24 24. 24. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,- 3 10 0 0 0 0 1
racic Society, racic r ra rac raci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 , 1 8 0 0 0 0 1
Medicine, et medicine, M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 ,.[-- 5 9 0 0 0 0 1
sus on sus s su sus sus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 no 0 9 0 0 0 0 1
China]. Zhonghua china]. C Ch Chi Chin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 ].., 4 8 0 0 0 0 1
44(4):292-310 44(4):292-310 44(4):292-310 4 44 44( 44(4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 ():- 4 2 0 0 0 0 1
25. Editorial 25. 2 25 25. 25. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 . 1 10 0 0 0 0 1
Diseases. Clinical diseases. D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 . 1 10 0 0 0 0 1
application of application a ap app appl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 8 0 0 0 0 1
sequencing (In sequencing s se seq sequ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ().. 4 8 0 0 0 0 1
2020;38(11):681-9. 2020;38(11):681-9. 2020;38(11):681-9. 2 20 202 2020 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 ;():-. 6 3 0 0 0 0 1
26. Yang 26. 2 26 26. 26. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,. 5 10 0 0 0 0 1
polymyxin antimicrobial polymyxin p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 no 0 9 0 0 0 0 1
clinical interpretation. clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 ..;(): 6 9 0 0 0 0 1
1-16. 1-16. 1-16. 1 1- 1-1 1-16 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 -. 2 1 0 0 0 0 1
27. Pogue 27. 2 27 27. 27. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,. 5 10 0 0 0 0 1
susceptibility testing susceptibility s su sus susc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 : 1 10 0 0 0 0 1
recommendations from recommendations r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 - 1 8 0 0 0 0 1
tee on tee t te tee tee BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 no 0 8 0 0 0 0 1
(USCAST). (USCAST). (uscast). ( (U (US (USC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 9 (). 3 1 0 0 0 0 1
Antimicrob Antimicrob antimicrob A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 9 no 0 2 0 0 0 0 1
Agents Agents agents A Ag Age Agen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 no 0 1 0 0 0 0 1
Chemother. Chemother. chemother. C Ch Che Chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 9 . 1 2 0 0 0 0 1
2020;64(2):e01495-e1519. 2020;64(2):e01495-e1519. 2020;64(2):e01495-e1519. 2 20 202 2020 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 ;():-. 6 4 0 0 0 0 1
28. Khwaja 28. 2 28 28. 28. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .. 2 10 0 0 0 0 1
acute kidney acute a ac acu acut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 .. 2 7 0 0 0 0 1
2012;120(4):c179-184. 2012;120(4):c179-184. 2012;120(4):c179-184. 2 20 201 2012 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 10 ;():-. 6 4 0 0 0 0 1
29. Lu 29. 2 29 29. 29. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,,,,,. 8 9 0 0 0 0 1
Efficacy and efficacy E Ef Eff Effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 10 no 0 9 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 - 1 10 0 0 0 0 1
resistant organism resistant r re res resi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 .(- 3 8 0 0 0 0 1
sanne). 2022;9:1067548. sanne). s sa san sann BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 ).;:. 5 4 0 0 0 0 1
30. Ayoub 30. 3 30 30. 30. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 ..: 3 10 0 0 0 0 1
review of review r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 9 0 0 0 0 1
resistance. Membranes resistance. r re res resi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 .().;():. 9 9 0 0 0 0 1
Infect Dis infect I In Inf Infe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 ():- 4 10 0 1 1 0 0
153 153 153 1 15 153 153 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 11 no 0 1 0 1 0 0 0
31. Stefaniuk 31. 3 31 31. 31. BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,.- 4 10 0 1 0 0 1
obacterales strains obacterales o ob oba obac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 -.. 3 9 0 1 0 0 1
2019;68(4):417-27. 2019;68(4):417-27. 2019;68(4):417-27. 2 20 201 2019 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 0 ;():-. 6 3 0 1 0 0 1
32. Rodriguez 32. 3 32 32. 32. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 10 0 1 0 0 1
In vitro in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 11 0 no 0 10 0 1 0 0 1
Acinetobacter baumannii acinetobacter A Ac Aci Acin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 . 1 9 0 1 0 0 1
J Infect j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 0 .;():-. 7 7 0 1 0 0 1
33. Pankuch 33. 3 33 33. 33. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 1 .,,,. 5 10 0 0 0 0 1
meropenem with meropenem m me mer mero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 1 no 0 8 0 0 0 0 1
colistin against colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 1 - 1 9 0 0 0 0 1
tobacter baumannii. tobacter t to tob toba BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 1 .- 2 7 0 0 0 0 1
mother. 2008;52(1):333-6. mother. m mo mot moth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 1 .;():-. 7 4 0 0 0 0 1
34. Gordon 34. 3 34 34. 34. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,. 4 9 0 0 0 0 1
and sustained and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 - 1 10 0 0 0 0 1
colistin combination colistin c co col coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 - 1 9 0 0 0 0 1
strains of strains s st str stra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 . 1 9 0 0 0 0 1
Agents Chemother. agents A Ag Age Agen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 2 .;():-. 7 7 0 0 0 0 1
35. Zusman 35. 3 35 35. 35. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,,. 5 10 0 0 0 0 1
monotherapy or monotherapy m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 - 1 8 0 0 0 0 1
bapenem-resistant bacteria: bapenem-resistant b ba bap bape BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 -: 2 9 0 0 0 0 1
meta-analysis. meta-analysis. meta-analysis. m me met meta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 -. 2 2 0 0 0 0 1
J J j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 2 no 0 0 0 0 0 0 1
Antimicrob Antimicrob antimicrob A An Ant Anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 2 no 0 2 0 0 0 0 1
Chemother. Chemother. chemother. C Ch Che Chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 2 . 1 2 0 0 0 0 1
2017;72(1):29-39. 2017;72(1):29-39. 2017;72(1):29-39. 2 20 201 2017 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 2 ;():-. 6 3 0 0 0 0 1
36. Nutman 36. 3 36 36. 36. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,,. 5 10 0 0 0 0 1
plus meropenem plus p pl plu plus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 -- 2 8 0 0 0 0 1
negative infections: negative n ne neg nega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 :- 2 9 0 0 0 0 1
ciated with ciated c ci cia ciat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 3 . 1 10 0 0 0 0 1
Infect. 2020;26(9):1185-91. infect. I In Inf Infe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 3 .;():-. 7 5 0 0 0 0 1
37. Saelim 37. 3 37 37. 37. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,,. 5 10 0 0 0 0 1
Colistin plus colistin C Co Col Coli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 4 - 1 10 0 0 0 0 1
bapenem-resistant bapenem-resistant bapenem-resistant b ba bap bape BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 - 1 3 0 0 0 0 1
acinetobacter acinetobacter acinetobacter a ac aci acin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 no 0 2 0 0 0 0 1
baumannii: baumannii: baumannii: b ba bau baum BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 : 1 2 0 0 0 0 1
improved efficacy improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 - 1 10 0 0 0 0 1
city? Infect city? c ci cit city BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 ?.;():-. 8 8 0 0 0 0 1
38. Covington 38. 3 38 38. 38. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,,. 4 10 0 0 0 0 1
monitoring as monitoring m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 : 1 9 0 0 0 0 1
review of review r re rev revi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 .. 2 9 0 0 0 0 1
2018;38(5):569-81. 2018;38(5):569-81. 2018;38(5):569-81. 2 20 201 2018 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 5 ;():-. 6 3 0 0 0 0 1
39. Dias 39. 3 39 39. 39. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 10 0 1 0 0 1
C-reactive protein c-reactive C C- C-r C-re BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 - 1 9 0 1 0 0 1
hospitalized patients: hospitalized h ho hos hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 :- 2 9 0 1 0 0 1
analysis. BMC analysis. a an ana anal BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;():. 7 7 0 1 0 0 1
40. Henriquez-Camacho 40. 4 40 40. 40. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .-,.- 5 10 0 1 0 0 1
sis. Biomed sis. s si sis sis. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ..;:. 5 7 0 1 0 0 1
41. Pogue 41. 4 41 41. 41. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .,,. 4 10 0 0 0 0 1
around the around a ar aro arou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 - 1 9 0 0 0 0 1
polymyxins? Int polymyxins? p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 ?.;(): 6 9 0 0 0 0 1
622-6. 622-6. 622-6. 6 62 622 622- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 -. 2 1 0 0 0 0 1
42. Azad 42. 4 42 42. 42. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .,,,. 5 10 0 0 0 0 1
of polymyxin-induced of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 -. 2 8 0 0 0 0 1
Med Biol. med M Me Med Med BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 8 .;:-. 5 5 0 0 0 0 1
43. Wang 43. 4 43 43. 43. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .,,,. 5 9 0 0 0 0 1
polymyxin-induced nephrotoxicity polymyxin-induced p po pol poly BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 8 -- 2 8 0 0 0 0 1
tors in tors t to tor tors BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 8 :-. 3 10 0 0 0 0 1
World J world W Wo Wor Worl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 8 .;():-. 7 7 0 0 0 0 1
44. Sisay 44. 4 44 44. 44. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,,.-- 7 10 0 0 0 0 1
duced nephrotoxicity duced d du duc duce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 :- 2 9 0 0 0 0 1
atic review atic a at ati atic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 - 1 9 0 0 0 0 1
using RIFLE using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 .- 2 9 0 0 0 0 1
macol Res. macol m ma mac maco BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 .;:. 4 5 0 0 0 0 1
45. Hao 45. 4 45 45. 45. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,,.- 6 9 0 0 0 0 1
mens with mens m me men mens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 no 0 10 0 0 0 0 1
monotherapy in monotherapy m mo mon mono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 no 0 9 0 0 0 0 1
by carbapenem-resistant by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 --. 3 9 0 0 0 0 1
Antibiotics (Basel). antibiotics A An Ant Anti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 10 ().;():. 8 7 0 0 0 0 1
Publisher's Note publisher's P Pu Pub Publ BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 ' 1 10 0 0 0 0 1
Springer Nature springer S Sp Spr Spri BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 11 - 1 10 0 0 0 0 1
tional claims tional t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 8 0 0 0 0 1
affiliations. affiliations. affiliations. a af aff affi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 . 1 2 0 0 0 0 1
154 154 154 1 15 154 154 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 11 no 0 1 0 1 0 0 0
Infect Dis infect I In Inf Infe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 ():- 4 10 0 1 1 0 0

